Akhu Therapeutics is developing medicine to outperform antidepressants, and break down naturally for safety to users and the environment.
Online PR News – 13-August-2016 – Irvine, California – environmental safety might not be the first thing that comes to mind when thinking about treatments for depression and anxiety. Nonetheless, antidepressants (e.g., Prozac) and anxiolytics (e.g., Valium) have been reported to accumulate in waterways and adversely affect fish and other aquatic animals. To solve that problem, Akhu Therapeutics, Inc., a small biotech company, is developing a new class of medicine for anxiety and depression.
Akhu’s blockers of MC5R (the melanocortin-5 receptor) are biodegradable peptides that will not accumulate in the brain, body, or waterways. So, they are expected to be significantly less toxic to people and the environment. How well could this new medicine work on depression and anxiety? MC5R blockers are up to 3X more effective and 1000X faster acting than antidepressants in proven animal models of anxiety and depression. Millions of people take antidepressants for depression and anxiety, but they don’t work for half of all users and take 6 weeks when they do work. Anxiolytics work faster on anxiety, but are addictive.
Akhu Therapeutics is crowdfunding the next phase of this work through an Indiegogo Campaign, to prepare their medicine for use in people. You can help them complete their mission by making a donation.
Safe Harbor Statement
Some statements made here may constitute forward-looking statements under securities laws. Such statements are based on projections, future expectations, and assumptions concerning factors, risks, and uncertainties that could significantly affect anticipated results and, accordingly, may cause actual results to differ materially from those expressed in the forward-looking statements. The statements made herein are not guaranties of future performance.